Shares of Cerulean Pharma Inc. (NASDAQ:DARE) have been given a consensus recommendation of “Hold” by the six research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $3.00.
Separately, ValuEngine raised shares of Cerulean Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, July 22nd.
Cerulean Pharma (DARE) traded down 2.90% during trading on Friday, reaching $2.68. The company’s stock had a trading volume of 18,878 shares. Cerulean Pharma has a 52 week low of $2.63 and a 52 week high of $35.80. The firm has a 50-day moving average price of $4.87 and a 200-day moving average price of $7.60. The firm’s market capitalization is $7.78 million.
TRADEMARK VIOLATION NOTICE: This story was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://stocknewstimes.com/2017/08/21/cerulean-pharma-inc-dare-receives-3-00-consensus-price-target-from-brokerages.html.
Cerulean Pharma Company Profile
Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.
Receive News & Ratings for Cerulean Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
